Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an announcement.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of December 11, 2025, the company has bought back a total of 2,521,446 ordinary fully paid securities, including 250,000 on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, focusing on providing pathology services. The company is involved in the analysis of medical samples and diagnostics, catering to both public and private healthcare sectors.
Average Trading Volume: 794,599
Technical Sentiment Signal: Buy
Current Market Cap: A$552.5M
For detailed information about ACL stock, go to TipRanks’ Stock Analysis page.